

تحت رعاية سمو الشيخ خالد بن محمد بن زايد آل نهيان، ولي عهد أبوظبي رئيس المجلس التنفيذي لإمارة أبوظبي

Under the Patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council

Towards longevity, redefining health and well-being

AN ABU DHABI STRATEGIC INITIATIVE

THE FORUM @ ADGHW BROCHURE



Abu Dhabi Global
Health Week

FOUNDATION PARTNER

M2

HOSTED BY

دائرة الصحة
DEPARTMENT OF HEALTH



15 - 17 APRIL 2025
ADNEC CENTRE ABU DHABI, UAE

ORGANISED BY **dmg::events**

Chairman's Message



It is my pleasure to welcome you to the second edition of Abu Dhabi Global Health Week (ADGHW), a borderless partnership designed to bring forward the future of healthcare and life sciences for a healthier world. We aim to inspire and enable leaders from across the world to create and together achieve a bold, collective vision for a brighter future of global health.

I look forward to global leaders engaging in open, inclusive exchanges and joint actions to solve future health challenges today.

Thanks to Abu Dhabi's close-knit community, diverse population, and continued investments in healthcare infrastructure, we are ideally equipped to help make access to quality and innovative healthcare a reality for all. Here we can trial and scale innovative healthcare solutions, from genomics to our fast growing centre for preventative and precision medicine. Here we provide world class care to patients for the best possible outcomes to enable both a healthy population and a flourishing society.

With an emphasis on fast tracking life sciences, health innovation, sustainability, and preventative and personalised medicine, Abu Dhabi Global Health Week will provide an unrivalled experience and a holistic platform for researchers, policy makers, healthcare specialists, investors, and entrepreneurs from across disciplines and geographies to unlock shared opportunities. The event will deliver advisory plans based on insights across three key areas: collaboration, leadership, and healthcare innovation.

Deeply integrated into Abu Dhabi's trusted healthcare system – with its track record of excellence and fast growing, future-forward, data-enabled services – ADGHW will readily transform ideas into action. Held in Abu Dhabi, with and for the world, ADGHW provides an always-on platform for open, inclusive exchange and joint action for a healthier world. Together we can make good health and quality care a universal standard.

His Excellency
Mansoor Ibrahim Al Mansoori

CHAIRMAN
DEPARTMENT OF HEALTH, ABU DHABI

About the Host Abu Dhabi Department of Health

Abu Dhabi serves as the
gateway between the
GCC, MENA, and global
regions.

Renowned for its world-leading medical infrastructure, Abu Dhabi is a premier destination for medical tourism, precision medicine, and life sciences innovation.

Abu Dhabi has achieved several key milestones in its healthcare journey and continues to strengthen its position as a leading destination for advanced healthcare as well as an incubator for innovation in life sciences.

Abu Dhabi Global Health Week takes place in a regional hub for international cooperation and unification where strategies, policies and opportunities are made by those that lead the healthcare sector.

Abu Dhabi's healthcare sector has reaffirmed its flexibility and readiness to confront crises and faces challenges while continuing to provide healthcare services at the highest levels of quality and using the latest therapeutic, preventive and diagnostic innovations and technologies.

HIGHLIGHTS

Abu Dhabi as the gateway to the GCC and MENA health and medical care landscape.

EMPHASISES

Abu Dhabi's role in fostering a sustainable and resilient healthcare and life science ecosystem on a global scale.

POSITIONS

Abu Dhabi as a global leadership hub for the healthcare and life science industries.

DEMONSTRATES

The UAE's diversification and sustainable economic growth agenda.

UNDERLINES

Abu Dhabi's achievements and future plans in biopharmaceutical manufacturing and biotech initiatives.

FORUM @ ADGHW AGENDA



Hear from leading minds in healthcare

As Abu Dhabi Global Health Week returns for its second edition, the **Forum@ADGHW** will serve as the event's centrepiece, providing a platform for debate and collaboration among government and industry leaders, experts, and academics over 2.5 days.

The 2025 edition will focus on the core theme: **Towards longevity: Redefining health and wellbeing**. Together, we will explore how we can live healthier, happier, and longer lives, addressing key questions to shape the future of global health.

The event emphasises community-driven health, with a proactive approach centred on preventive, personalised, and holistic care. Four core pillars will guide our conversations and initiatives:

- **Longevity & precision health:** Personalising the future of medicine
- **Health system resilience & sustainability:** Crafting future-ready frameworks
- **Digital health & AI:** Revolutionising care through technology
- **HEAL & investment in life sciences:** Driving global innovation forward

Advances in healthcare have dramatically extended lifespans. A century ago, life expectancy was 25 years shorter than today, and by 2050, the global average age is expected to reach 78.1 years. However, disparities in healthcare access, rapid urbanisation, and rising chronic diseases challenge our systems. At the same time, technologies like AI and digital health platforms offer unprecedented opportunities to transform care.

Addressing these challenges requires a shift from reactive treatment to a proactive, personalised approach to health. By 2040, healthcare spending will prioritise well-being and preventive measures, supported by advancements in human biology and innovative therapies.

The choices we make today will shape global health for generations. Through collaboration, we can build resilient health systems, leverage technology to expand access, and ensure these advancements are accessible to all, regardless of location or socioeconomic status.

Forum @ ADGHW speakers

and thought leaders



H.E. MANSOOR AL MANSOORI
Member of The Abu Dhabi Executive Council
Chairman of The Department of Health in Abu Dhabi, UAE



H.E. DR. NOURA AL GHAITHI
Undersecretary
Department of Health,
Abu Dhabi, UAE



H.E. DR. JEAN KASEYA
Director General
Africa Centres for Disease Control and Prevention (Africa CDC)



H.E. DR. RASHED ALSUWAIDI
Director General
Abu Dhabi Public Health Center (ADPHC)



CIYONG ZOU
Deputy to the Director General and Managing Director;
Directorate of Technical Cooperation and Sustainable Industrial Development
United Nations Industrial Development Organization (UNIDO)



JIM MELLON
Co-Founder, Deputy Chairman
Juvenescence



PROF. ERAN SEGAL
Professor and Department Chair of Computational Biology, MBZUAI
Professor of Computer Science, Weizmann Institute of Science



TAREK SULTAN
Chairman
Agility Global



SIR JONATHAN SYMONDS
CBE, Chair
GSK, UK



DR. SHAMSHEER VAYALIL
Founder and Chairman
Burjeel Holdings, UAE



BAYNA AL AWANI
Director General of Healthcare Payers and Finance Affairs
Department of Health
Abu Dhabi, UAE



H.E. IBRAHIM AL JALLAF
Executive Director of Digital Health
Department of Health
Abu Dhabi, UAE



DR. ASMA AL MANNAEI
Executive Director, Research and Innovation Centre
Department of Health
Abu Dhabi, UAE



H.E. PROF. DR. KHALED ABDEL-GHAFFAR
Deputy Prime Minister for Human Development and Minister of Health & Population
Arab Republic of Egypt



H.E. ANAHIT AVANESYAN
Minister of Healthcare
Republic of Armenia



DR. MISHAL ALQASIMI
Chief Executive Officer
Capital Health



PROF. RAGHIB ALI
CEO, Chief Investigator and Chief Medical Officer
Our Future Health



SHAISTA ASIF
Group Chief Executive Officer
PureHealth



ISABEL AFONSO
CEO
Arcera, UAE



DR. PETER ATTIA
Physician, podcast host, and author
Early Medical



H.E. MIKHAIL MURASHKO
Minister of Health
Russian Federation



H.E. SAMI SMEIRAT
Minister Digital Economy and Entrepreneurship
Jordan



H.E. DR. JALEELA BINT ASAYED JAWAD HASAN
Minister of Health
Bahrain



H.E. ADONIS GEORGIADIS
Minister of Health
Hellenic Republic



H.E. FIRAS IBRAHIM AL-HAWARI
Minister of Health
Jordan



DR. DAVID BARZILAI
Founder and CEO, Barzilai Longevity Consulting | Faculty and Trustee, Geneva College of Longevity Science
Healthspan Coaching LLC | agingdoc.com



ELENA BONFIGLIOLI
Global Business Leader, GM Healthcare, Pharma, and Life Sciences
Microsoft, Belgium



ARYA BOLURFRUSHAN
Founder and CEO
AppliedAI, UAE



DR. OLA BROWN
General Partner and Founder
HealthCap Africa



MADLINE BELL
CEO
Children's Hospital of Philadelphia, USA



H.E. DR. MIKHEIL SARJVELADZE
Minister of Internally Displaced Persons from the Occupied Territories, Health, Labor and Social Affairs
Georgia



H.E. DR. THANI BIN AHMED AL ZEYUODI
Minister of State for Foreign Trade and Minister in charge of Talent Attraction and Retention
Ministry of Economy, UAE



H.E. DR. HUSSAIN ABDUL RAHMAN AL RAND
Assistant Undersecretary for the Public Health Sector
Ministry of Health Prevention, UAE



LEYMAH GBOWEE
Liberian Peace and Women's Rights Activist and Nobel Peace Prize Winner, 2011;
Founder and President
Gbowee Peace Foundation Africa (GPFA), Liberia



NERIO ALESSANDRI
Founder and Chief Executive Officer
Technogym



KEVIN B. CHURCHWELL, MD
President and CEO
Boston Children's Hospital, USA



DR. THOMAS CLOZEL
Co-Founder and CEO
Owkin, USA



DR. MIKE CURTIS
President and Chief Executive Officer
eGenesis



DR. STEVE DAVIS
President and CEO
Cincinnati Children's Hospital Medical Center
USA



DR. ABASI ENE-OBONG
Founder and Chief Executive Officer
Syndicate Bio



DR. AYMAN AL HENDY
Professor, Department of Obstetrics and Gynecology, Pritzker School of Medicine, University of Chicago, and Professor & Chair, Department of Medical Sciences, Khalifa University, Abu Dhabi, UAE



HUBERTUS VON BAUMBACH
Chairman of the Board of Managing Directors and Chief Executive Officer
Boehringer Ingelheim



MICHEL DEMARÉ
Chair
AstraZeneca



DR. PETER KASH
Co-founder, TargImmune Therapeutics and iOncologi;
Chairman, Camelot BioCapital, USA



TSITSI MASIYIWA
Executive Chair and Co-founder
Higherlife Foundation



DR. KHALID FAKHRO
Chief Research Officer
Sidra Medicine



DR. STEFAN FRINGS
Chief Medical Officer
Pharma Development
Roche



DR. HEITHAM HASSOUN
Chief Executive International
Cedars-Sinai Medical Center



DR. GEORGE PASCAL HABER
Chief Executive Officer
Cleveland Clinic Abu Dhabi



H.E. DR. FARIDA AL HOSANI
Deputy Chief Executive Officer
Global Institute for Disease Elimination (GLIDE)

Forum @ ADGHW speakers

and thought leaders



DR. KAMRAN KHAN
Founder and CEO
BlueDot, Canada



PROF. AYMERIC LIM
Chief Executive Officer
National University Hospital
NUHS



SHERRIE LIM
Chief Executive Officer
Mount Elizabeth Novena Hospital



DR. RICHARD JENKINS
Chief Medical Officer
PwC Middle East, KSA



DR. MICHELLE LONGMIRE
Chief Executive Officer,
Co-founder
Medable



CHRIS WHARTON
Founder and
CEO
WndrHLTH



PENG XIAO
GROUP CEO
G42



HON WENG CHONG
Founder &
Chief Executive Officer
Cortical Labs



DR. CHRISTINE YUAN HUANG
Founder and Chief Executive
Officer, Quantum Life
Technology Transfer Director,
Hong Kong Quantum AI Lab
(HKU, InnoHK)



DR. ALEX ZHAVORONKOV
Founder and CEO
Insilico Medicine, USA



KEVIN B. MAHONEY
Chief Executive Officer
University of Pennsylvania
Health System



DR. JAMES MAULT
Chief Executive Officer
BioIntelliSense



DR. TOMISLAV MIHALJEVIC
CEO and President
Morton Mandel CEO Chair
Cleveland Clinic, USA



ALISHA MOOPEN
Managing Director and
Group Chief Executive Officer
Aster DM Healthcare, UAE



DR. BARRY MERRIMAN
Adjunct Professor of Synthetic
Biology, J. Craig Venter Institute;
Chief Science Officer & Co-Founder,
Avery Bioengineering Inc. & Roswell
Molecular Electronics Inc., USA



DR. HESHAM A. ABDULLAH
Senior Vice President,
Global Head Oncology,
Research & Development
GSK



MOHAMMAD ABOUBAKR
Regional Vice President
Middle East, Africa and
Russia CIS
Abbvie, UAE



DR. LINDA BEDRAN
Senior Vice President & Head of
Corporate Affairs, JANZ & Emerging
Markets
Viatris



ALI BESRI
Vice President, Emerging Markets
Access and Accord Lead
Pfizer Inc



ALEX BEAUVAIS
Partner
McKinsey&Company, UK



YOSHIHIKO NAKAMURA
Chief Executive Officer
Kinescopic, Inc.



MOHAMED NASSER
AVP General Manager
Amgen in the Middle East
& Africa (MEA)



DR. SANIA NISHTAR
CEO
GAVI, Switzerland



HASAN JASEEM AL NOWAIS
Managing Director and
Group Chief Executive Officer
M42



JULIA MIAO
Deputy Chief Executive Officer
and Chief Financial Officer
Sihuan Pharmaceuticals



DR. NICOLAS CHEMALI
Senior Vice President,
International Value and Access
Eli Lilly International



DR. PATRICK HORBER
President of International Unit
Novartis



DR. DAVID KATZ
CEO, DietID; President
True Health Initiative



DR. RICHARD L. LIEBER
Chief Scientific Officer & Senior
Vice President of Research
Shirley Ryan AbilityLab



DR. CECILIA RADU
Vice President
General Manager
Novo Nordisk, UAE



DR. TOM OXLEY
Chief Executive Officer
Synchron



PRITHVIRAJ PRAMANIK
Co-founder and CEO
AQAI, India



DR. MATTHEW SHAW
Chief Executive Officer
Great Ormond
Street Hospital



DR. NICOLE SIROTIN
CEO
Institute for Healthier Living
Abu Dhabi, UAE



ANIL SONI
Chief Executive Officer
WHO Foundation



TALA AL RAMAHI
on behalf of
Mohamed bin Zayed
Foundation for Humanity



DR. ISKRA REIC
Executive Vice-President,
International
AstraZeneca



EMMA RAWSON-TE PATU
President
World Federation of Public
Health Associations



JIM SWANSON
Executive Vice President and
Chief Information Officer
Johnson & Johnson



LAURA M. SWINT
Vice President, Digital Health
and AI Leader, META
Eli Lilly



KÁRI STEFÁNSSON
CEO, Founder
deCODE genetics, Iceland



DIEGO SANTORO
Head of International
Markets
Kite, Gilead, Brazil



JACOB THAYSEN
CEO
Illumina, USA



PRASHANT TANDON
Co-founder and
CEO
Tata 1mg, India



BJOERN VON SIEMENS
Founder and
CEO
Caresyntax



DR. PAVEL VOLCHIKOV
CEO
Life Science
Research Center
MIPT, RUSSIA




TONY TERZIS
Associate Vice President,
Medical Affairs, META
Eli Lilly



IRINA ZAPOROZHETS
President and General
Manager (META)
Eli Lilly and Company



DR. NIR BARZILAI
Director of the Institute
for Aging Research
Albert Einstein College
of Medicine



OLFAT BERRO
Area Head Middle East
Roche Pharmaceuticals

Forum @ ADGHW speakers

and thought leaders



PROF. QUEK SWEE CHYE
Chairman of the Medical Board
NUS - Singapore



ALESSANDRO BORGOGNA
Chief Cluster Economic
Development
Abu Dhabi Investment Office



DR. TOBY COSGROVE
Executive Advisor, **Cleveland
Clinic**, Former CEO and
President USA



PROF. DR. GEORGE DEMETRI
Institute Physician
Senior Vice President for
Experimental Therapeutics,
Founding Director, **Sarcoma
Center, USA**



DR. JICUI DONG
Head of the Local Production
and Assistance Unit
WHO



FARAH FAKHOURI
Founder of Wave Health
Consultancy
UAE



HADLEY GAMBLE
International Correspondent
and TV News Anchor; Host,
the Hadley Gamble Show



DR. PANCO GEORGIEV
Senior Partner
McKinsey



ALI HASHEMI
Co-Founder and CEO
meta[bolic]



DR. STEPHEN R. GROBMYER
Institute Chair of the
Cancer Institute
Cleveland Clinic Abu Dhabi



DR. BETTINA ERNST
Vice President
Swiss Biotech Association (SBA)



PROF. HABIBA AL SAFAR
Dean of the College of Medicine
and Health Sciences
Khalifa University



DR. STEVE HORVATH, PHD
Principal Investigator
Altos Labs, USA



HADY A. KHOURY
Chief Development Officer
Medable



DR. JAMES KIRKLAND
Director of the Center for
Advanced Gerotherapeutics &
Professor of Medicine
Cedars-Sinai Medical Center



PROF. DR. SHAHEER HASHMI
Director of Research
**Department of Health
Abu Dhabi**



DR. LARS HARTENSTEIN
Director of Healthy Longevity
McKinsey Health Institute, France



DR. MIRA MOUSA
Assistant Professor, Public Health
and Epidemiology
Khalifa University



PROF. ELIAS MOSSIALOS
Cheng Yu Tung
Chair in Global Health
**The London School
of Economics and Political
Science**



SHANNON MARC NEILSEN
Director Longevity
PureHealth



PROF. ANDREA MAIER
Oon Chiew Seng Professor in
Medicine, **National University
of Singapore**; Co-Founder,
**NUS Academy for Healthy
Longevity, National University
of Singapore, Singapore**



DR. TLALENG MOFOKENG, MD
UN Special Rapporteur
on the Right to Health
United Nations



DR. MAKOTO NAKANISHI
Professor, The Institute
of Medical Science
The University of Tokyo



**DR. MIGUEL ANGELO
L. NICOLELIS**
Professor Emeritus
of Neurobiology
Duke University



PROF. GREGORY A. PETSKO
Professor of Neurology
**Harvard Medical School and
Brigham & Women's Hospital**



LARA SETRAKIAN
Journalist & President
**Applied Policy Research
Institute, USA**



MINNI SÄRKKÄ-HIETALA
Health and Human Services
Leader, Europe
Deloitte, Finland



LINA SHADID
Health Industries Lead
PwC Middle East



ANNA STEWART
International Correspondent
CNN, UK



SUMIT SHARMA
Partner and IMEA Head,
Health & Life Sciences
Oliver Wyman



EDDIE REILLY
Head of Global Regulatory Affairs
and Chief Regulatory Officer,
Research and Development
Sanofi



ELODIE ROBIN-GUILLERM
Head of Global Clusters
**Abu Dhabi Investment Office
(ADIO)**



DR. SAMIR SAID
Healthcare Informatics Leader,
Middle East, Türkiye, Africa, Russia
and Central Asia
Philips



DR. CHRISTIAN SINA
Professor of Medicine and Director
**The Institute of Nutritional
Medicine at University Hospital
Schleswig-Holstein, Lübeck,
Germany**



DR. JENNIFER STONE
Co-Chair Indiana Consortium for
Integrative Medicine and Health
**Indiana University School
of Medicine, USA**



H.E. DR. AMIN HUSSAIN AL AMIRI
Assistant Undersecretary for the
Health Regulation Sector
**Ministry of Health and Prevention
- UAE (MoHAP)**



AHMED MOHAMED AL BASTAKI
Advisor, General Secretary
**National Supreme for Unified
Procurement, UAE**



**DR. ALI ABDUL KAREEM
AL OBAIDLI**
Chairman
**UAE National Transplant
Committee**



KELSEY WARNER
Gulf Reporter
Semator



DR. MARIA GOMEZ
Director, National Regulatory Center
for Donation and Transplantation of
Human Organs and Tissues, UAE
Ministry of Health and Prevention, UAE



DR. DIANA TORGENSEN
Head of Innovation Ecosystem
Integration
Organon



ALDHABI ALMHEIRI
Entrepreneur, Publisher, Founder
Rainbow Chimney, UAE



BECKY ANDERSON
Host, CNN Connect,
Managing Editor
CNN Abu Dhabi



HAMISH CLARK
Health Industries Partner
PwC, UAE



ELSY DUMIT
Principal
Roland Berger, UAE

Day 1: Tuesday, 15 April 2025

09:30 – 09:40

In Conversation with H.E. Mansoor Ibrahim Al Mansoori

One-on-one Conversation

The Chairman of the Department of Health opens the day with a conversation on how data, innovation, and a personalized approach to public health are shaping a new era of longevity for communities in the UAE and around the world.



H.E. Mansoor Ibrahim Al Mansoori
Chairman
Department of Health – Abu Dhabi, UAE



Anna Stewart
International
Correspondent
CNN, UK
Moderator



09:40 - 10:05

Life Sciences Investment: What type of Business Environment Accelerates Investment

Panel discussion

A strong business environment is essential for fostering innovation and investment in life sciences. Effective policies, regulatory frameworks, and financial incentives play a crucial role in attracting research and development, while demographic factors such as population health trends and market demand further shape the industry's growth. In an increasingly competitive global landscape, regions that strategically align these elements can position themselves as leading life sciences hubs. Abu Dhabi stands out with its rapidly growing life sciences cluster, leveraging targeted investments, advanced infrastructure, and supportive policies to drive innovation and international collaboration. Understanding these factors provides valuable insights into what makes a life sciences ecosystem thrive.

Why now?

With over AED 1 billion in investments, Masdar City Free Zone is set to become a leading life sciences hub in Abu Dhabi. Hosting 50+ biotechnology companies and cutting-edge R&D facilities, it fosters innovation in rare diseases, genomics, cell and gene therapy, and clinical trials.

Impact goals

Drive investment into Abu Dhabi's life sciences cluster (HEAL) by showcasing incentives, regulatory regime and population diversity.

Guiding questions

- What key policies, regulations, and financial incentives are most effective in attracting investment and fostering innovation in life sciences?
- How do population health trends, workforce availability, and regional demand shape the growth and sustainability of a life sciences ecosystem?
- What strategies and investments have positioned Abu Dhabi as an emerging global hub for life sciences, such as its cutting-edge research in genomics and the establishment of the Abu Dhabi Global Market (ADGM) Life Sciences Centre, and what lessons can other regions learn?



Isabel Afonso
CEO
Arcera, UAE



Alessandro Borgogna
Advisor to the Director General
Abu Dhabi Investment Office



Dr. Bettina Ernst
Vice President
Swiss Biotech
Association,
Switzerland



Dr. Peter Kash
Co-founder, TargImmune
Therapeutics and
iOncologi; Chairman,
Camelot BioCapital, USA



Sumit Sharma
Partner and IMEA Head, Health &
Life Sciences
Oliver Wyman, UAE
Moderator

10:05 - 10:15

The ROI on Women's Health

Panel discussion

What happens when we treat women's health not as a line item, but as a global investment strategy? Nobel Peace Prize Laureate Leymah Gbowee, renowned peacebuilder and women's rights activist, shares her powerful perspective on why investing in women's health is not only a moral imperative—but an economic one. Drawing from her work with the Gbowee Peace Foundation Africa, she will explore the transformative potential of prioritizing women's health, the ripple effects across families, communities, and nations, and the urgent need for bold leadership and financing to close the gender health gap.

Why now?

Women's health has long been underfunded, overlooked, and under-measured—despite overwhelming evidence of its catalytic impact on economic growth, community stability, and intergenerational wellbeing. As the global community faces compounding crises—conflict, climate change, economic strain—the cost of inaction is mounting. With an estimated \$1 trillion in lost productivity tied to gender health inequities, the world cannot afford to wait. This is a critical moment to reframe women's health as a strategic investment—and drive collective action.

Impact goals

To highlight effective partnership models that bridge industry, research, and healthcare delivery

Guiding questions

- What are the long-term costs of failing to invest in women's health—economically, socially, and politically?
- How can funders and policymakers shift from treating women's health as a siloed issue to embedding it in peace, security, and development strategies?
- What role does community-based leadership—especially by women in fragile contexts—play in designing impactful health investments?
- What concrete actions can governments, donors, and the private sector take now to close the gender health gap?



Leymah Gbowee
Liberian Peace and Women's Rights Activist and Nobel Peace Prize Winner, 2011;
Founder and President
Gbowee Peace Foundation Africa (GPFA), Liberia

10:15 - 10:50

Collaborating for Impact: Partnerships in Health Innovation

Panel discussion

Effective partnerships between researchers, healthcare providers, and industry leaders are transforming health innovation. By leveraging strategic collaboration, stakeholders can accelerate medical breakthroughs, enhance patient outcomes, and tackle global health challenges. This panel will explore successful partnership models, the power of data-driven research, and strategies for navigating ethical and regulatory complexities to maximize impact.

Why now?

In 2024, global health R&D investment reached \$265 billion, with the private sector contributing nearly two-thirds. Venture capital in health tech rebounded, with strong interest in AI drug discovery, digital therapeutics, and women's health. Over 70% of new medical innovations since 2020 involved cross-sector collaboration. Governments are also backing innovation ecosystems—like those in Abu Dhabi, Boston, and Heidelberg—bringing together academia, startups, regulators, and providers to accelerate regulation, data access, and talent development.

Impact goals

To highlight effective partnership models that bridge industry, research, and healthcare delivery

Guiding questions

- What partnership models are proving most effective in accelerating innovation across research, industry, and healthcare delivery?
- How can industry, research institutions, and healthcare providers align incentives and capabilities to accelerate impact?
- How can partners navigate the ethical, regulatory, and data governance challenges that come with shared innovation efforts?
- What role do innovation ecosystems play in driving health R&D, and how can we strengthen them through targeted investment and policy support?



Dr. Hesham A. Abdullah
Senior Vice President,
Global Head Oncology,
Research & Development
GSK, UK



Mohammad Aboubakr
Regional Vice President for
Middle East, Africa and Russia
AbbVie, UAE



Hubertus von Baumbach
Chairman of the Board of
Managing Directors and
Chief Executive Officer
**Boehringer Ingelheim
Germany**



Dr. Heitham Hassoun
CEO for International,
Professor of Surgery
Cedars-Sinai, USA



Dr. Diana Torgersen
Head of Innovation Ecosystem
Integration
Organon, USA



Farah Fakhouri
Founder
**Wave Health Consultancy
UAE**

Moderator

10:50 - 11:10

Catalysts for Change: Collaborative Giving for Health Equity

Panel discussion

Philanthropic organizations are pivotal partners in advancing health equity and catalyzing systemic change. From supporting essential health services, to bringing innovations within reach of underserved populations, philanthropic funding has emerged as a crucial lever to bridge gaps, mobilize resources, and strengthen health systems. Today, the rise of collaborative giving is providing a new vehicle for delivering change at scale, joining resources, diverse partners, and expertise to unlock new opportunities and drive sustainable progress against complex global health challenges.

Why now?

In 2025, a significant trend in healthcare philanthropy is the rise of collaborative giving, where donors pool resources to address complex global health challenges more effectively; philanthropic giving is projected to exceed \$1 trillion globally.

Impact goals

To explore how philanthropic collaboration can unlock transformative solutions for global health equity

Guiding questions

- How can collaborative giving accelerate access to health services in underserved communities, and what models are showing the most promise?
- What shifts in mindset or infrastructure are needed to build trust and alignment among diverse philanthropic partners, and between funders and local leaders?
- How can local leadership and community-driven priorities shape more effective, equitable funding strategies?
- How can philanthropy better support grassroots and community-led solutions to drive meaningful health and social change?
- How can collaborative giving models ensure they are truly inclusive of women, youth, and communities closest to the challenges?



Tsitsi Masiyiwa
Co-Founder and Chair
Delta Philanthropies and
Higherlife Foundation, UK



Tala Al Ramahi
on behalf of
Mohamed bin Zayed
Foundation for Humanity
UAE



Lara Setrakian
Journalist & President
Applied Policy Research
Institute, USA

Moderator

11:10 - 11:30

Unified Procurement Program: A Strategic Leap for Healthcare Sustainability in the UAE

Panel discussion

Robust procurement systems are the backbone of resilient, efficient, and sustainable healthcare. This session will spotlight the UAE's Unified Procurement Program as a bold national effort to strengthen procurement infrastructure, enhance coordination across providers, and ensure long-term value for the healthcare system. Panelists will explore how unified procurement supports cost containment, supply chain resilience, and better health outcomes—laying the foundation for a more sustainable future.

Why now?

With global healthcare supply chain disruptions increasing by over 60% since 2020 (WHO, 2023), centralized healthcare procurement programs have been shown to reduce total expenditures and potential to improve cost-efficiency in national health systems.

Impact goals

Showcase UPP as a healthcare reform milestone, align with UAE Vision 2031, and emphasize cross-agency collaboration and a future roadmap.

Guiding questions

- What were the primary motivations behind the launch of the Unified Procurement Program (UPP), and what challenges did it aim to address?
- What have been the key achievements of the UPP since its inception, and how have they contributed to national health outcomes?
- How were diverse stakeholders aligned and engaged in the design and implementation of the UPP?
- What have been the financial and strategic impacts of the UPP on procurement efficiency, cost containment, and healthcare delivery in the UAE?
- What are the future plans for scaling the UPP, and how can its model be adapted or replicated across other regions or sectors?



H.E. Dr. Amin Hussain Al Amiri
Assistant Undersecretary
Health Regulation Sector,
Ministry of Health and
Prevention, UAE



Bayna Al Awani
Director General of Healthcare
Payers and Finance Affairs,
Department of Health
Abu Dhabi, UAE



Ahmed Mohamed Al Bastaki
Advisor General Secretary
National Supreme for Unified
Procurement, UAE



Elsy Dumit
Principal
Roland Berger, UAE

Moderator

11:30 – 12:00

Rethinking Healthcare Funding

Panel discussion

As aging populations grow and the prevalence of chronic conditions rises, traditional health funding and insurance models are under increasing strain. At the same time, medical advancements and digital health innovations are transforming how care is delivered. Harnessing data-driven approaches – such as predictive analytics, personalized risk assessments, and value-based care models – could pave the way for more efficient, affordable, and outcome-focused healthcare systems. Exploring these novel models will be key to ensuring sustainable financing, improving patient outcomes, and making quality care more accessible in the years ahead.

Why now?

Population ageing is accelerating in almost all countries around the world: by 2074, the global population aged 65 and older is expected to reach 20.7% from 10.3% in 2024, while the number of people aged 80 and above is projected to more than triple.

Impact goals

Support the implementation of promising, new, data-driven funding models for healthcare in countries with aging populations.

Guiding questions

- How can data be leveraged to ensure more affordable care and better outcomes?
- What are the most promising tools under development?
- How can regulation and collaboration support the roll out of the most promising tools?



Dr. Ola Brown
General Partner and Founder
HealthCap Africa, Nigeria



Dr. Linda Bedran
Senior Vice President & Head
of Corporate Affairs, JANZ &
Emerging Markets
Viatris, UAE



Anil Soni
Chief Executive Officer
WHO Foundation
Switzerland



Mohamed Nasser
Associate Vice President and
General Manager
Amgen, UAE



Dr. Nicolas Chemali
Senior Vice President,
International Value and Access
Eli Lilly International



Kelsey Warner
Gulf Reporter
Semafor, UAE

Moderator

12:00 – 12:45

Lunch or Networking

12:45 – 13:45

Opening Ceremony | Health for Humanity: Improving Life for All

Special Address, Panel Discussion, Welcome Show

As healthcare rapidly evolves, three key areas are driving the future of longevity and patient outcomes. AI and digital health are revolutionizing diagnosis, treatment, and personalized care, leveraging big data, machine learning, and virtual health solutions to enhance accessibility and efficiency. System resilience and sustainability have become critical in the face of global challenges, with a focus on strengthening healthcare infrastructure, ensuring equitable access, and integrating environmentally sustainable practices. Longevity and precision health are advancing through innovations in genomics, regenerative medicine, and targeted therapies, redefining aging and disease prevention. In this high-level plenary, Dr. Peter Attia will draw from his pioneering work in preventative care and precision health to outline a future where healthspan, not just lifespan, is the new metric of progress. Peng Xiao will spotlight how AI and next generation digital infrastructure can democratize access, accelerate innovation, and drive systemic change at scale. The session will chart an ambitious agenda for action, setting the stage for two and a half days of bold ideas and cross-sector collaboration.

Why now?

Global life expectancy is forecasted to increase from 73.6 years of age in 2022 to 78.1 years of age in 2050 (a 4.5-year increase).

Impact goals

Identifying the most salient opportunities and challenges to be addressed over the next two days. Drive action on AI and digitalization, longevity and investment into resilience of health systems.

Guiding questions

- Why is investing in health and longevity critical for economic and social well-being in the 21st century?
- How can AI and digital health improve access, efficiency, and personalization while addressing privacy concerns?
- What breakthroughs in longevity and precision medicine have the greatest potential to extend healthy lifespan?
- How do we balance innovation with scalability, ensuring access to cutting-edge care across regions and populations?
- What role should leaders in tech and medicine play in building health systems that are future-ready and human-centered?

Opening Remarks by



H.E. Mansoor Ibrahim Al Mansoori
Chairman
Department of Health – Abu Dhabi, UAE



Dr. Peter Attia
Physician
Podcast host, and Author, USA



Peng Xiao
Group CEO
G42, UAE



Becky Anderson
Managing Editor, CNN
Abu Dhabi & Anchor, **Connect the World with Becky Anderson**, UAE

Moderator

13:45 – 14:00

Interlude + Interactive Audience Engagement

14:00 - 14:30

The New Era of Organ Transplantation

Panel discussion

Organ transplantation is undergoing rapid transformation across the region, driven by regulatory reform, cross-border collaboration, and medical innovation. Timely adoption of global best practices—such as those outlined in the WHO’s recommendations and reflected in the UAE’s 2023 law—is helping to establish clear, ethical, and responsive systems. Key developments in complex, multi-organ transplants and the integration of advanced techniques, including robotic-assisted procedures, point to a future where regional systems are equipped to deliver high-quality care across a wide range of transplant needs. This session explores how regional partnerships are enabling complementary transplant services between countries, strengthening the broader ecosystem. It also highlights the critical role of capacity-building—starting with medical professionals, legal teams, and logistics networks—as a foundation for future public engagement.

Why now?

Rising demand and technological advances—such as multi-organ and robotic-assisted transplants—are reshaping what is possible in regional care delivery.

Impact goals

To explore how policy reform, innovation, and regional cooperation are strengthening organ transplantation system, and to identify the next steps in building capacity, fostering public trust, and ensuring ethical, high-quality care for all.

Guiding questions

- What foundations are needed to create a coordinated, ethical, and scalable transplant ecosystem across countries?
- How can regulatory alignment and knowledge-sharing accelerate access to advanced procedures and improve patient outcomes?
- What investments in workforce, logistics, and legal infrastructure are most urgent to support regional transplant systems?
- How can public awareness and trust be built around organ donation and transplantation in a culturally responsive way?



H.E. Dr. Rashed Al Suwaidi
Director General
Abu Dhabi Public Health
Center, UAE



H.E. Dr. Amin Hussain Al Amiri
Assistant Undersecretary
Health Regulations Sector
MoHAP, UAE



Dr. Ali Abdul Kareem Al Obaidli
Chairman
UAE National Transplant
Committee, UAE



Dr. George Pascal Haber
CEO
Cleveland Clinic
Abu Dhabi, UAE



Dr. Maria Gomez
Director, National Regulatory
Center for Donation and
Transplantation of Human
Organs and Tissues
UAE Ministry of Health and
Prevention, UAE

Moderator

14:30 – 14:35

Remarks by Dr. Mark Hyman*

*Pre-recorded video

14:35 – 15:00

Breaking the Age Barrier: The Science and Strategy of Longevity

Expert Dialogue

As global interest in longevity grows, the conversation is shifting from simply adding years to life, to adding life to years. This panel explores cutting-edge developments in aging science, from the biology of aging and translational geroscience to innovation in clinical care and digital health. Drawing on perspectives from research, healthcare delivery, and emerging technologies, the discussion will highlight how science and innovation are reshaping what it means to age well—and what this means for individuals, health systems, and societies.

Why now?

Global life expectancy is forecasted to increase from 73.6 years of age in 2022 to 78.1 years of age in 2050 (a 4.5-year increase). This is a critical moment to harness new discoveries, reimagine care models, and ensure that longevity gains translate into better quality of life for all.

Impact goals

To deepen the dialogue from the opening panel, explore healthy longevity as a multidisciplinary frontier, and spark collaboration among researchers, clinicians, and innovators.

Guiding questions

- What are the most promising scientific developments in aging and longevity research today?
- How can we translate breakthroughs in geroscience into clinical care and public health impact?
- What role do digital health and AI play in advancing healthy aging?
- How can health systems prepare for and support longer, healthier lives across diverse populations?
- What ethical, equity, and accessibility considerations must be addressed in the pursuit of longevity?
- How do we shift cultural mindsets from treating aging as decline to viewing it as a stage of opportunity and innovation?



Dr. James Kirkland
Director of the Center for
Advanced Gerotherapeutics &
Professor of Medicine
Cedars-Sinai Medical Center
USA



Prof. Andrea Maier
Oon Chiew Seng
Professor in Medicine,
National University of
Singapore; Co-Founder,
NUS Academy for Healthy
Longevity, National University
of Singapore, Singapore



Dr. Nicole Sirotin
CEO
Institute for Healthier
Living Abu Dhabi, UAE



Tony Terzis
Associate Vice President
Medical Affairs (META)
Eli Lilly



Anna Stewart
International Correspondent
CNN, UK

Moderator

15:00 – 15:25

Scaling Precision Medicine in Longevity

Panel discussion

Precision medicine is revolutionizing healthcare by tailoring treatments to individuals based on their genetic, environmental, and lifestyle factors. As the potential of personalized care expands, a key challenge is how to scale these innovations to make them accessible, affordable, and effective for all populations. This includes redesigning health systems to integrate advanced diagnostics, targeted therapies, and personalized prevention strategies. As life expectancies rise, the focus shifts to ensuring that these advancements not only extend lifespans but also enhance the overall quality of life, creating a sustainable and equitable healthcare model for the future.

Why now?

The market size for precision medicine is estimated at USD 102.17 billion in 2024 with a growth of 16.5% until 2034. In the US, the average cost of precision medicine treatments is estimated at almost 300,000 USD (in 2024).

Impact goals

Identify pathways to scaling precision medicine from a cost perspective and pave the way for the most promising innovations of the next years.

Guiding questions

- What are the main challenges and solutions for making precision medicine affordable and accessible to all, especially in low-resource areas?
- How can health systems integrate personalized medicine on a large scale, and what changes in infrastructure or policy are needed?
- As life expectancy rises, how can precision medicine improve both lifespan and quality of life for different populations?



Dr. David Barzilai
Founder and CEO, Barzilai
Longevity Consulting | Faculty
and Trustee, Geneva College of
Longevity Science
Healthspan Coaching LLC, USA



Elena Bonfiglioli
Global Business Leader,
General Manager,
Healthcare, Pharma, and
Life Sciences
Microsoft, Belgium



Dr. Mike Curtis
President and CEO
eGenesis



Dr. Makoto Nakanishi
Professor, The Institute of
Medical Science
The University of Tokyo
Japan



Jacob Thaysen
CEO
Illumina, USA



Dr. Stephen R. Grobmyer
Institute Chair of the
Cancer Institute
Cleveland Clinic
Abu Dhabi, UAE

Moderator

15:25 – 15:55

A Holistic Approach to Community and Health and Longevity

In collaboration with AI Shifaa Summit for Integrative Medicine

Panel discussion

As the focus on longevity and well-being grows, integrative and lifestyle medicine are emerging as powerful tools to enhance community health. By combining conventional treatments with evidence-based complementary therapies, alongside preventive health strategies, we can address the whole person—mind, body, and spirit. Holistic wellness practices, including balanced nutrition, physical activity, stress management, and social connectivity, play a critical role in disease prevention and longevity. This session brings together thought leaders, innovators, and practitioners to explore the latest advancements in integrative and lifestyle medicine, public health strategies, and culturally adapted wellness interventions.

Why now?

The global rise in chronic, lifestyle-related diseases and mental health challenges is exposing the limitations of reactive healthcare models. At the same time, there is growing demand for more holistic, personalized approaches to health that prioritize prevention, resilience, and well-being. Advances in science, technology, and behavior change—paired with a cultural shift toward self-care and longevity—make this the ideal moment to mainstream integrative and lifestyle medicine as a foundation for healthier individuals and communities.

Impact goals

To catalyze the integration of lifestyle and holistic health approaches into public health and clinical practice—bridging science, policy, and innovation to support longer, healthier lives through whole-person care.

Guiding questions

- How can digital platforms and behavioral science support scalable, sustainable wellness habits across nutrition, movement, and daily life?
 - What tools and strategies can make healthy eating and active living more accessible, actionable, and central to preventive care?
 - How can integrative medicine, blending lifestyle, clinical care, and holistic approaches, improve outcomes, support longevity, and enhance system-wide cost-effectiveness?
 - What cross-sector models are most effective in advancing integrative, lifestyle-based health solutions, from policy to tech to clinical practice?
- What role can government and regulatory bodies play in integrating lifestyle and integrative medicine into mainstream healthcare systems?



H.E. Dr. Noura Al Ghaithi
Undersecretary
Department of Health
Abu Dhabi, UAE



Nerio Alessandri
Founder & CEO
Technogym, Italy



Dr. David Katz
CEO, **DietID**; President,
True Health Initiative



Dr. Jennifer Stone
Co-Chair Indiana Consortium for
Integrative Medicine and Health
Indiana University School of
Medicine, USA



Chris Wharton
Founder and
Chief Executive Officer
WndrHLTH, USA



Shannon Marc Neilsen
Director – Longevity
PureHealth, UAE

Moderator

15:55 – 16:00

Announcement

16:00- 16:10

Biomarkers: An Update on Epigenetic Clocks

Impulse Talk

Environmental factors such as pollution, diet, and stress can have lasting effects on our genes, influencing the aging process. DNA methylation levels and epigenetic clocks, like the Horvath Clock, are powerful tools for measuring biological age and the cumulative impacts of these environmental exposures. By assessing these markers, scientists can gain valuable insights into how environmental factors affect gene expression, the potential for reversing these effects, and how this knowledge could inform future strategies for aging and health interventions. How might this understanding shape the future of aging research and interventions?

Why now?

The epigenetics industry is expected to be worth USD 4.3 billion by 2028, with a CAGR of 18.3%.

Impact goals

Create shared understanding of the potential of epigenetic clocks and drive investment into related tools.

Guiding questions

- How can future research uncover the long-term effects of pollution and lifestyle on DNA methylation and aging?
- How can epigenetic clocks help predict and track biological aging, and how might they be used in personalized health strategies?
- Can interventions reverse the genetic impact of environmental stressors on aging, and what breakthroughs could make this possible?



Dr. Steve Horvath, PhD
Principal Investigator
Altos Labs, USA

16:10 – 16:35

Exploring the Potential of Targeted Therapies

Panel discussion

Advancements in precision medicine are revolutionizing the treatment of age-related conditions, including cancer, cardiovascular diseases, and Alzheimer's. Targeted therapies, driven by breakthroughs in genomics, biomarkers, and personalized medicine, offer more effective and tailored approaches to managing these complex diseases. As research progresses, these innovations have the potential to not only improve patient outcomes but also extend healthy lifespan.

Why now?

The global targeted therapeutics market, valued at USD 80.14 billion in 2024, is expected to reach USD 155.20 billion by 2034, growing at a CAGR of 6.83%. The small molecule segment will likely see the fastest growth, with breast cancer treatments expected to experience the highest growth rate.

Impact goals

Create a shared understanding on which developments hold the most promise and how they can be effectively implemented, which will be key to shaping the future of healthcare for aging populations.

Guiding questions

- What emerging targeted therapies have the potential to transform the treatment of age-related diseases in the next decade?
- How will advancements in genomics, AI, and biomarker-driven treatments shape the future of personalized healthcare for aging populations?
- What strategies and innovations are needed to make cutting-edge targeted therapies more accessible, affordable, and effective on a global scale?



H.E. Dr. Jaleela bint AlSayed Jawad Hasan
Minister of Health
Bahrain



Prof. Dr. George Demetri
Institute Physician Senior
Vice President, **Experimental Therapeutics**, Founding Director,
Sarcoma Center, USA



Jim Mellon
Co-Founder, Deputy Chairman
Juvenescence, UK



Diego Santoro
Head of International
Markets
Kite, Gilead, Brazil



Kári Stefánsson
CEO, Founder
deCODE genetics, Iceland



Dr. Stephen R. Grobmyer
Institute Chair of the
Cancer Institute
Cleveland Clinic Abu Dhabi, UAE

Moderator

16:35 – 16:55

Weight-loss Drugs: A Gamechanger for Longevity

Panel discussion

Emerging research suggests that weight-loss drugs may offer significant health benefits beyond addressing obesity, potentially aiding in the management of a variety of chronic and degenerative conditions, including Alzheimer’s disease. These medications are being explored for their role in tackling age-related conditions such as cardiovascular disease, diabetes, and neurodegenerative disorders. By targeting underlying mechanisms like inflammation and metabolic dysfunction, weight-loss drugs may contribute to extending healthy lifespan and improving overall quality of life in aging populations.

Why now?

1 in 8 people are now living with obesity worldwide. The World Obesity Federation predicts that by 2030, 1 billion people around the world will be obese, including 1 in 5 women and 1 in 7 men. The weight loss market is expected to see 16 new drugs by 2029 according to Morningstar and Pitchbook.

Impact goals

Enable stakeholders to take more informed decisions regarding the potential numerous benefits of weight loss drugs, potential applications, risks and regulatory challenges.

Guiding questions

- How can weight-loss drugs evolve to treat chronic and age-related conditions?
- What’s needed to ensure their long-term safety, efficacy, and accessibility?
- How can healthcare systems integrate them into aging and disease prevention strategies?



Dr. Cecilia Radu
Vice President
General Manager
Novo Nordisk, UAE



Dr. Richard Jenkins
Chief Medical Officer
PwC Middle East, KSA



Irina Zaporozhets
President, General Manager
of the Middle East and Turkey
Area (META)
Eli Lilly and Company, UAE



Prof. Dr. Shahrukh Hashmi
Director of Research
Department of Health
Abu Dhabi, UAE

Moderator

16:55 – 17:00

Announcement

17:00 - 17:25

Novel Therapeutic Strategies for Healthy Longevity

In collaboration with Khalifa University

Panel discussion

From nutritional interventions to cutting-edge biosensors and precision therapies, emerging innovations are transforming the pursuit of healthy longevity. Advances in regenerative medicine, gene therapy, and metabolic interventions are redefining how we extend healthspan and prevent age-related diseases. This session will explore how novel therapeutic strategies, including precision approaches for women’s health, are shaping the future of aging and wellness. Experts will discuss the latest scientific breakthroughs, from cellular rejuvenation to personalized health monitoring, offering insights into the next frontier of longevity medicine.

Why now?

Aging populations and the rise of chronic, age-related diseases are straining health systems worldwide. Simultaneously, scientific breakthroughs in nutrition, biosensing, and regenerative medicine are creating new possibilities for extending healthspan—not just lifespan. As these innovations move closer to clinical and consumer application, now is a pivotal time to explore their potential, ensure they are inclusive (especially in areas like women’s health), and accelerate their integration into real-world practice.

Impact goals

To highlight how emerging therapies, nutritional science, and personalized health technologies are converging to transform the landscape of healthy aging—shifting the paradigm from disease treatment to proactive, precision-driven longevity strategies

Guiding questions

- What role do nutritional interventions play in preventing age-related diseases and promoting long-term wellness?
- How are biosensors and wearable technologies enabling more precise, personalized health monitoring for longevity?
- What are the most promising innovations in regenerative and gene therapies for enhancing healthy aging?
- How can precision medicine approaches better address gender-specific aging patterns and women’s health needs?
- How can academic institutions and biotech innovators collaborate to accelerate healthy longevity breakthroughs?



Prof. Habiba Al Safar
Dean, College of Medicine
and Health Sciences Professor
in Genomic at Biomedical
Engineering Department,
Khalifa University, UAE



Dr. Ayman Al Hendy
Professor, Department of
Obstetrics and Gynecology,
Pritzker School of Medicine,
University of Chicago, and
Professor & Chair, Department
of Medical Sciences, Khalifa
University, Abu Dhabi, UAE



Dr. Barry Merriman
Adjunct Professor of Synthetic
Biology, J. Craig Venter Institute;
Chief Science Officer &
Co-Founder, Avery
Bioengineering Inc. & Roswell
Molecular Electronics Inc., USA



Dr. Christian Sina
Professor of Medicine
and Director
The Institute of Nutritional
Medicine at University
Hospital Schleswig-Holstein,
Lübeck, Germany



Dr. Mira Mousa
Assistant Professor, Public Health
and Epidemiology
Khalifa University, UAE

Moderator

17:25 – 17:55

What's Next for Gene Editing and Cellular Gene Therapies

Panel discussion

Gene editing is revolutionizing medicine by offering targeted treatments for inherited conditions, particularly those affecting the blood, muscles, and nervous system. With the recent FDA approval of gene therapy for severe sickle cell disease, the field is rapidly advancing toward new applications. Researchers are now exploring which conditions could be next to benefit from approved gene therapies, including muscular dystrophies, rare genetic disorders, and neurodegenerative diseases. As these technologies progress, the focus shifts to overcoming scientific, ethical, and regulatory challenges to ensure broader access to life-changing treatments.

Why now?

The global gene editing market, valued at USD 9.30 billion in 2024, is projected to reach USD 40.10 billion by 2034, growing at a CAGR of 15.73%. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, cell line engineering, and reagents/consumables are expected to drive significant growth.

Impact goals

Create a shared understanding of pathways to overcoming scientific, ethical and regulatory challenges to ensure broader access to treatments based on gene editing, for specific diseases.

Guiding questions

- Which conditions could benefit next from FDA-approved gene therapies following sickle cell disease?
- What scientific, ethical, and regulatory challenges must be addressed to expand gene therapy access globally?
- How will CRISPR and other gene-editing technologies shape the future of precision medicine and genetic disease treatment?



Dr. Abasi Ene-Obong
Founder and
Chief Executive Officer
Syndicate Bio, USA



Dr. Patrick Horber
President International
Novartis, Switzerland



Prof. Eran Segal
Professor and Department
Chair of Computational
Biology, MBZUAI Professor
of Computer Science,
Weizmann Institute of
Science, UAE



Dr. Pavel Volchikov
CEO
Life Science
Research Center
MIPT, RUSSIA



Prof. Dr. Shahrukh Hashmi
Director of Research
Department of Health
Abu Dhabi, UAE

Moderator

Day 2: Wednesday, 16 April 2025

HEALTH SYSTEM RESILIENCE & SUSTAINABILITY

09:30 – 09:35

Remarks by Dr. Tedros Adhanom Ghebreyesus, Director General, WHO*
*Pre-recorded video

9:35 – 10:05

21st Century Health Systems

Panel discussion

Many aspects of modern healthcare—from hospital infrastructure to insurance models—are still rooted in 20th-century designs and methodologies. As demographics shift, medical advancements accelerate, and patient expectations evolve, healthcare systems must adapt to remain effective and sustainable. Future-ready healthcare requires rethinking hospital planning, financing models, and service delivery to better accommodate aging populations, digital health innovations, and personalized medicine. Exploring the key priorities for transformation will be essential to ensuring that healthcare systems are resilient, efficient, and equipped to meet the demands of the coming decades.

Why now?

The global health spending (expenditures with regards to healthcare services and goods) as a share of GDP is projected to rise steadily from 2024 to 2029, increasing by 0.2 percentage points. By 2029, it is expected to reach a new peak of 6.31%, from 6.07% in 2024.

Impact goals

Identify future challenges and concrete pathways to future-proofing health systems in light of emerging megatrends.

Guiding questions


- What are the key megatrends that will shape health systems of the next decades?
- Where are the 3 most important areas for action in order to future-proof the healthcare systems in the region and globally?
- For each of these areas of action what types of solutions are needed?
- What approaches can be taken to address both the challenges and opportunities these trends present?



H.E. Mansoor Ibrahim Al Mansoori
Chairman
Department of Health
Abu Dhabi, UAE



H.E. Anahit Avanesyan
Minister of Health
Armenia



Shaista Asif
Group CEO
PureHealth, UAE



Michel Demaré
Chair
AstraZeneca, Switzerland



Dr. Shamsheer Vayalil
Founder and Chairman
Burjeel Holdings, UAE



Moderator

Becky Anderson
Managing Editor
CNN Abu Dhabi & Anchor,
Connect the World with
Becky Anderson, UAE
adghw.com

10:05 – 10:35

Health Equity: New Priorities for Impact

In collaboration with Partnership for Health System Sustainability and Resilience (PHSSR)

Panel discussion

Global and national development actors, along with philanthropic organizations, have been instrumental in driving public health progress over the past decades, achieving milestones such as polio vaccination, improved sanitation, and enhanced maternal and child health. As health challenges continue to evolve, new priorities are emerging in areas such as infectious disease control, health equity, and sustainable healthcare systems. This shift demands stronger collaborations and innovative approaches from both new and established leaders in global health, as they work together to create lasting, transformative impact.

Why now?

In 2023, global development assistance for health declined to USD 64.6 billion. If health remains a priority for development partners, the Institute for Health Metrics and Evaluation forecasts that this assistance will further decrease to USD 50.6 billion by 2030. However, if other sectors take priority, it could potentially fall to USD 36.7 billion.

Impact goals

Create a shared understanding among stakeholders on future priorities for impact and how collaboration among stakeholders can be strengthened to address them.

Guiding questions

- What specific actions can be taken today to tackle the most urgent global health challenges?
- What are the priorities for impact for the next 5-10 years?
- Where is collaboration and pooling of resources most important in light of the changing development landscape?
- Who should take the lead in addressing these priorities?
- What is the role of public-private partnerships in enhancing health equity?



H.E. Prof. Dr. Khaled Abdel-Ghaffar
Deputy Prime Minister for Human Development and Minister of Health & Population
Arab Republic of Egypt



H.E. Dr. Mikheil Sarjveladze
Minister of Internally Displaced Persons from the Occupied Territories, Health, Labor and Social Affairs
Georgia



Dr. Tlaleng Mofokeng, MD
UN Special Rapporteur on the Right to Health
United Nations, South Africa



Emma Rawson-Te Patu
President
World Federation of Public Health Associations
New Zealand



Iskra Reic
Executive Vice-President International
AstraZeneca, Switzerland



Moderator

Prof. Elias Mossialos
Cheng Yu Tung Chair in Global Health
The London School of Economics and Political Science, UK

10:35 – 11:05

Leadership Against Emerging Infectious Threats

Panel discussion

Zoonotic diseases and antimicrobial resistance (AMR) represent two of the most urgent and interconnected global health threats of our time—placing growing strain on health systems, especially in regions facing resource challenges or high biodiversity. As countries work to build resilient, responsive health systems, regional and global cooperation is essential to detect and contain outbreaks, safeguard treatments, and protect communities. This panel brings together health leaders to explore how national policies, regional coordination, and global partnerships can reinforce preparedness, scale innovation, and ensure equitable access to both preventive and curative solutions.

Why now?

AMR could cost the global economy up to \$3.4 trillion in GDP losses by 2030, while zoonotic spillovers are increasing due to climate change and human-animal interactions. These dual threats are converging, exposing gaps in preparedness and demanding urgent, coordinated action.

Impact goals

To catalyze increased investment, policy alignment, and cross-sector collaboration to strengthen surveillance, innovation, and equitable access to solutions addressing both AMR and emerging zoonotic threats.

Guiding questions

- What are the most promising opportunities to prevent and respond to zoonotic diseases and AMR—from next-generation therapies to early detection tools?
- How can countries build stronger, more coordinated surveillance systems to track zoonotic outbreaks and antimicrobial resistance across borders?
- What roles can international collaboration, public-private partnerships, and regional health institutions play in advancing scalable, sustainable solutions?
- How can financing, regulatory, and health system reforms ensure equitable access to prevention, diagnostics, and treatments in vulnerable and high-risk regions?



H.E. Dr. Jean Kaseya
Director General
Africa Centres for Disease Control and Prevention, Ethiopia



H.E. Mustapha Ferjani
Minister of Health
Tunisia



H.E. Adonis Georgiadis
Minister of Health
Hellenic Republic, Greece



H.E. Firas Ibrahim Al-Hawari
Minister of Health
Jordan



H.E. Dr. Hussain Abdul Rahman Al Rand
Assistant Undersecretary
The Public Health Sector
Ministry of Health Prevention, UAE



Moderator

Hadley Gamble
Chief International Anchor
Al-Arabiya, UK

11:05 – 11:20

Smart and Sustainable Health Systems

Panel discussion

Health systems are under growing pressure from climate change, population growth, and shifting disease burdens. To meet the demands of the future, governments and innovators must rethink how health services are powered, delivered, and scaled. This panel explores how clean energy, digital transformation, and regional cooperation are coming together to build smart, sustainable, and resilient health systems across the Middle East and beyond.

Why now?

As climate change threatens to cause 250,000 additional deaths annually by 2050 and global healthcare demand is set to rise over 50%, health systems face urgent pressure to adapt. Digital innovation offers a dual solution—telehealth alone can reduce emissions by up to 70 times per visit, while AI and data tools can boost system efficiency by 20–30% and cut waste across supply chains, which account for 71% of the sector’s carbon footprint.

Impact goals

Promote cross-sector action to integrate digital innovation and clean energy into health systems, advancing resilience, equity, and climate adaptation across developing and emerging economies.

Guiding questions

- What does a smart, sustainable, and digitally enabled health system look like by 2035, and what are the building blocks to get there?
- Why must governments embed health into climate, energy, and sustainability strategies now, and how can ministries beyond health help lead this shift?
- How is digital entrepreneurship unlocking new models of care and access in resource-constrained or rapidly growing populations?
- What role can global cooperation and emerging technologies like AI, real-time data, and green infrastructure play in shaping more equitable and resilient health systems?



H.E. Sami Smeirat
Minister
Digital Economy and
Entrepreneurship, Jordan



Ciyong Zou
Deputy to the Director General,
Managing Director, Directorate
of Technical Cooperation
and Sustainable Industrial
Development
UNIDO, Austria



Minni Särkkä-Hietala,
Health and Human
Services Leader, Europe
Deloitte, Finland
Moderator

11:20 – 11:40

Resilient Health Supply Chains

Panel discussion

The increasing reliance on advanced drugs and medical technologies has made healthcare supply chains more complex and vulnerable to disruptions. Material shortages, geopolitical instability, and logistical challenges can threaten patient safety and treatment continuity. To address these risks, healthcare systems must adopt proactive strategies to enhance supply chain resilience, ensuring consistent access to critical medicines and equipment. Strengthening collaboration between healthcare providers, governments, and industry leaders will be essential to creating more adaptive, sustainable, and secure supply networks for the future of global health.

Why now?

In 2023, 93% of healthcare providers experienced widespread product shortages. As of 2024, the Supply Chain Resiliency Report highlights 80% of healthcare providers and 84% of suppliers expect supply chain challenges to worsen or remain the same.

Impact goals

Reduce risks in health supply chains by informing and motivating collaboration among healthcare providers and governments.

Guiding questions

- Where are the most important risks from a regional perspective?
- What are some of the solutions that have worked in countries around the world?
- What are examples of successful collaboration among healthcare providers and governments to reduce supply chain risks in health?
- What are key success factors for these collaborations and how can they be replicated?



H.E. Dr. Thani Bin Ahmed Al Zeyoudi
Minister of State for Foreign Trade and
Minister in charge of Talent Attraction
and Retention
Ministry of Economy, UAE



Sir Jonathan
Symonds, CBE, Chair
GSK, UK



Tarek Sultan
Chairman
Agility Global, Kuwait



Anna Stewart
International Correspondent
CNN, UK
Moderator

11:40 – 11:45

Announcement

11:45 – 12:05

Population Health Innovation for the Next Generation of Care

Panel discussion

This session explores how large-scale population health initiatives, such as biobanks and preventive health programs, can enhance the resilience and sustainability of healthcare systems. By enabling early disease detection, data-driven decision-making, and precision medicine, these initiatives help reduce long-term healthcare costs, improve health equity, and strengthen preparedness for future health challenges. The discussion will highlight how leveraging population health data can drive more efficient, personalized, and proactive healthcare solutions.

Why now?

With chronic diseases causing over 70% of global deaths and healthcare spending projected to hit \$11 trillion by 2030, there is an urgent need to shift from reactive care to proactive, precision-based approaches. Biobanks and national health research programs are proving the potential of population health innovation to drive this transformation.

Impact goals

Highlight how population health initiatives—like biobanks, early detection programs, and health data integration—can strengthen health system sustainability and resilience.

Guiding questions

- How can population health initiatives such as biobanks and preventive programs improve early detection and long-term health outcomes?
- What are the key enablers of innovation in population health—from data governance to public engagement—and how can they be strengthened?
- How can population health data be leveraged to drive equity, efficiency, and preparedness across healthcare systems?
- What are the challenges and opportunities in scaling population health innovations within and across countries?



Prof. Raghib Ali
CEO, Chief Investigator and
Chief Medical Officer
Our Future Health, UK



Dr. Asma Al Mannaei
Executive Director, Research
and Innovation Centre
**Department of Health -
Abu Dhabi, UAE**



Elena Bonfiglioli
Global Business Leader, General
Manager, Healthcare, Pharma,
and Life Sciences
Microsoft, Belgium



Alex Beauvais
Partner
McKinsey&Company, UK

Moderator

12:05 – 12:30

The Doctor of the Future

Panel discussion

The doctor of the future will need to seamlessly integrate hard and soft skills, combining medical expertise with technological proficiency and human-centered care. As AI-driven diagnostics, advanced imaging, and digital health tools reshape primary care, physicians must adapt to new training models that emphasize both technical fluency and emotional intelligence. Mastering emerging technologies while maintaining empathy, critical thinking, and communication will be essential to delivering effective, patient-centered care. At the same time, addressing global healthcare workforce shortages requires reimagining medical education. Scalable solutions—such as AI-assisted learning, virtual simulations, and standardized cross-border training—can expand access to quality education and upskilling opportunities. By investing in innovative learning models, we can equip the next generation of healthcare professionals with the skills needed to navigate a rapidly transforming healthcare landscape while ensuring equitable access to care worldwide.

Why now?

AI tools are showing promise—reducing missed detections by up to 70% and taking over routine tasks—while technologies like micro-CTs and micro-MRIs are emerging as key growth areas. Yet despite these advances, surveys consistently show that patients still value empathy and personal connection. At the same time, the world could face a shortage of 10 million health workers by 2030, with the largest gaps in low- and lower-middle-income countries.

Impact goals

To reduce global healthcare workforce shortages by identifying promising avenues for international collaboration on medical training and qualifications, while articulating a clear vision of the key trends shaping the medical workforce of the future—empowering stakeholders to make more informed, future-ready decisions.

Guiding questions

- What are the most critical skills gaps in today's healthcare workforce, and how are they evolving?
- How will AI and advanced diagnostics reshape the role of healthcare professionals—particularly in primary care?
- What training models are needed to equip future doctors with both technological fluency and human-centered care skills?
- How can emerging technologies enhance, rather than replace, the doctor-patient relationship?



H.E. Dr. Rashed Alsuwaidi
Director General
**Abu Dhabi Public Health Center
UAE**



Sherrie Lim
CEO
**Mount Novena Hospital
Singapore**



Prof. Quek Swee Chye
Executive Director
**NUHS Institute of Clinical Quality,
National University Health
System, Singapore**



Dr. Panco Georgiev
Senior Partner, and Leader
**McKinsey's Healthcare
Systems & Services
Practice in EEMA, UAE**

Moderator

12:30 – 13:00

How Can Technology Improve Equitable Healthcare Access

Panel discussion

Nearly half of the world’s population faces barriers to healthcare due to poverty, geographic isolation, or both. Advances in technology—from AI-powered diagnostics to telemedicine and digital health education—have the potential to bridge this gap by supporting healthcare professionals in delivering timely, effective, and affordable care. By leveraging data-driven tools, remote monitoring, and innovative treatment solutions, technology can enhance early diagnosis, improve treatment planning, and expand healthcare access to underserved communities. The future of global health depends on harnessing these innovations to create more inclusive and equitable healthcare systems.

Why now?

Over half of the global population (about 4.5 billion people) still faces barriers to accessing essential healthcare, according to the WHO. For 1.3 billion of them, the cost of medical care isn’t just a financial burden; it’s a catalyst for deeper economic hardship, pushing individuals and families into poverty or even extreme poverty.

Impact goals

Increase investment in the most promising technology solutions that reduce barriers to accessing essential healthcare.

Guiding questions

- Which are the most critical barriers that people face when accessing essential healthcare?
- Which barriers to access can be addressed through the most promising technological solutions over the next 5 or 10 years?
- What is the market potential for these innovative solutions and how should these be funded?



Ali Besri
Vice President, Emerging Markets
Access and Accord Lead
Pfizer Inc, Morocco



Dr. Jicui Dong
Unit Head, Local Production
and Assistance Unit
World Health Organization
Switzerland



Alisha Moopen
Managing Director and
Group Chief Executive Officer
Aster DM Healthcare, UAE



Prashant Tandon
Co-founder, CEO
Tata 1mg, India



Moderator

Ali Hashemi
Co-Founder and CEO
meta[bolic], UAE

14:10 – 14:20

Leading the Shift: A Young Voice Driving Health Innovation

Fireside Chat

From children’s bookshelves to the hearts of communities, a new generation of young leaders is reimagining how we heal, connect, and build more compassionate societies. This session features Emirati entrepreneur and publisher AIDhabi AIMheiri, whose work inspires early childhood learning and emotional well-being through storytelling. As mental health needs rise and calls for community-driven care grow louder, this conversation explores how storytelling can be a powerful tool for healing, identity-building, and inclusive impact. AIDhabi reflects on her journey as a young changemaker and how creativity, empathy, and imagination can shape a healthier, more connected future.

Why now?

Youth under 30 make up over 60% of people in low- and middle-income countries yet remain underrepresented in health leadership. At the same time, child mental health and well-being are emerging as urgent global priorities, calling for fresh, youth-led perspectives on care, inclusion, and innovation.

Impact goals

To elevate youth-driven creativity and leadership as a critical force in advancing health equity, early childhood development, and inclusive systems change.

Guiding questions

- What inspired you to start your journey, and how did storytelling become your tool for impact?
 - What challenges did you face as a young leader, and how did you overcome them?
- How can we create spaces where more young people feel empowered to share their voices and lead change?



AIDhabi AIMheiri
Entrepreneur, Publisher, Founder,
Rainbow Chimney, UAE



Moderator

Hadley Gamble
Chief International Anchor
Al-Arabiya, UK

13:00 – 14:00

Lunch or Networking

14:20 – 14:40

Scaling Excellence: Global Collaboration for Regional Transformation

Panel discussion

As healthcare systems across the globe face rising costs, shifting patient needs, and rapid technological change, collaboration between world-class institutions and regional leaders has never been more critical. This fireside chat brings together visionary executives to explore how strategic partnerships, knowledge exchange, and shared innovation can accelerate transformation at scale. From workforce development to data-driven care, the conversation will unpack how global excellence can be adapted—and scaled—to meet regional priorities and drive sustainable impact.

Why now?

Rising demand for specialized care, value-based models, and tech-driven innovation is reshaping systems worldwide. Institutions like Cleveland Clinic—serving over 3.5 million patients globally—are leading this transformation, making strategic collaboration essential to localize and scale high-quality care.

Impact goals

To explore how global expertise and innovation can be adapted to local contexts through sustained collaboration, driving scalable, high-impact transformation across clinical care, digital health, and health system strategy.

Guiding questions

- What are the key ingredients for successful global-regional partnerships in healthcare, and how do they create lasting value?
- How can leading institutions balance excellence with adaptability when expanding models of care across diverse health systems?
- What role do workforce development, training, and leadership exchange play in scaling high-performance health systems?
- How can data, technology, and AI be leveraged within partnerships to deliver more personalized, efficient, and scalable care?



Dr. Tomislav Mihaljevic
CEO and President and
Morton L. Mandel CEO Chair
Cleveland Clinic, USA



Hasan Jasem Al Nowais
Managing Director, Group CEO,
M42, Chairman, Cleveland
Clinic Abu Dhabi, UAE



Hadley Gamble
Chief International Anchor
Al-Arabiya, UK
Moderator

14:40 – 15:10

Leading Through Transformation: Hospital CEOs on the Future of Healthcare

Panel discussion

In an era of rapid change, hospital CEOs are at the forefront of reshaping healthcare delivery, driving innovation, and ensuring patient-centered care. This panel brings together four top hospital executives to share their insights on navigating challenges such as workforce shortages, financial sustainability, digital transformation, and evolving patient expectations.

Why now?

Hospital CEOs are increasingly leading system-wide transformation as healthcare faces mounting pressures and new opportunities driven by digital innovation, workforce shifts, and evolving patient expectations.

Impact goals

Surface shared strategies for advancing innovation, workforce resilience, and financial stewardship within complex healthcare environments.

Guiding questions

- How are hospital leaders balancing short-term operational pressures with long-term transformation goals in today's evolving healthcare landscape?
- What strategies are proving most effective in responding to workforce shortages and building more resilient, empowered teams?
- How are digital innovation and data integration being leveraged to improve patient outcomes and streamline care delivery?
- In a time of rising costs and shifting reimbursement models, what does financial sustainability look like for leading health systems?



Madeline Bell
CEO
Children's Hospital of
Philadelphia, USA



Kevin B. Churchwell, MD
President and CEO
Boston Children's Hospital
USA



Dr. Steve Davis
President and CEO
Cincinnati Children's
Hospital Medical Center, USA



Kevin B. Mahoney
CEO
University of Pennsylvania
Health System, USA



Dr. Mishal AlQasimi
CEO
Capital Health, Specialized
Rehabilitation Hospital &
Health Shield Medical Center,
Consultant Pediatrics, UAE



Lara Setrakian
Journalist & President
Applied Policy Research
Institute, USA
Moderator

15:10 – 15:15

Announcement

DIGITAL HEALTH & AI

15:15 – 15:45

AI-powered Health Support: Transforming Care from Diagnosis to Recovery

Panel discussion

AI is transforming healthcare by optimizing diagnosis, treatment, and recovery. From surgical intelligence to patient monitoring and personalized care, AI-driven solutions are improving outcomes and efficiency. This session will explore how hospitals and healthcare providers can effectively integrate AI, address challenges in adoption and accessibility, and ensure seamless implementation in clinical workflows.

Why now?

Studies show AI can reduce diagnostic errors by up to 40% and improve operational efficiency by 20–30% in clinical workflows. AI in the operating room is rapidly advancing, with tools that improve efficiency by up to 30%, reduce complications, and unlock underutilized surgical data—transforming how hospitals enhance safety, performance, and outcomes.

Impact goals

To identify scalable, real-world strategies for integrating AI across healthcare delivery—informing policy, investment, and implementation pathways that enhance clinical efficiency, safety, and patient outcomes.

Guiding questions

- How is AI currently improving diagnosis, treatment, and recovery in real-world healthcare settings?
- What are the biggest barriers—technical, regulatory, or cultural—to scaling AI in clinical workflows, and how can they be overcome?
- How can healthcare systems ensure AI adoption supports equity, privacy, and patient trust while delivering measurable impact?
- What strategic investments and partnerships are essential for scalable, seamless AI integration across diverse health systems?



H.E. Ibrahim Al Jallaf
Executive Director Digital Health
Department of Health
Abu Dhabi, UAE



Arya Bolurfrushan
Founder and CEO
AppliedAI, UAE



Bjoern Von Siemens
Co-Founder and CEO
Caresyntax, UK



Laura M. Swint
Vice President, Digital Health
and AI Leader, META
Eli Lilly, USA



Dr. Samir Said
General Manager, Healthcare
Informatics Leader
Philips - Middle East, Türkiye,
Africa, Russia, and Central Asia,
UAE



Hamish Clark
Health Industries Partner
PwC, UAE

Moderator

15:45 – 16:10

Unlocking the Potential of Health Data: Trust and Privacy

Panel discussion

Training AI on large health datasets holds immense potential for driving advancements in personalized care, disease prevention, and medical research. However, the challenge of balancing data access with privacy, security, and trust remains a significant barrier. Developing models that allow for responsible data use while protecting sensitive health information will be crucial in maximizing the social and economic benefits of AI in healthcare. Finding this balance is key to ensuring that public goods are prioritized without compromising data security.

Why now?

The global big data in healthcare market is set to grow from USD 50.74 billion in 2024 to USD 145.42 billion by 2033, at a CAGR of 11.41%. However, trust remains a challenge, with only 44% of people expressing confidence in AI for healthcare. Concerns are particularly high in countries like the United States, France, and Switzerland (about 40%), while countries like China, India, and Mexico show more trust (around 20%).

Impact goals

Enabling leaders to build systems that ensure trust in data to unlock the full potential of AI in health and healthcare while balancing security and public good.

Guiding questions

- How can healthcare systems ensure secure and ethical access to large health datasets for AI training?
- What strategies can be implemented to foster trust between patients, providers, and AI developers regarding data use?
- How can data-sharing models be designed to protect privacy while enabling advancements in healthcare innovation?



Dr. Toby Cosgrove
Executive Advisor, **Cleveland Clinic**, Former CEO and President
USA



Dr. Christine Yuan Huang
Founder and CEO,
Quantum Life | Technology
Transfer Director, **Hong Kong Quantum AI Lab**
(HKU, InnoHK)



Dr. Matthew Shaw
CEO
Great Ormond Street Hospital



Jim Swanson
Executive Vice President and
Chief Information Officer
Johnson & Johnson



Hamish Clark
Health Industries Partner
PwC, UAE

Moderator

16:10 - 16:20

Biohacking: The Future of Health Optimization

Impulse talk

This session explores the evolving field of biohacking and its potential to revolutionize health optimization. From cutting-edge neuroscience and AI-driven biotechnology to personalized interventions, biohacking is pushing the boundaries of human performance, longevity, and well-being. The discussion will highlight the latest innovations, ethical considerations, and the role of emerging technologies in shaping the future of health and self-optimization.

Why now?

Advances in neuroscience, wearable tech, and AI-driven biotechnology are rapidly expanding the frontiers of biohacking—an industry projected to surpass \$60 billion by 2028. As individuals increasingly seek to optimize health, cognition, and longevity outside traditional healthcare, 2025 marks a turning point for defining the science, ethics, and accessibility of self-optimization tools.

Impact goals

To explore how emerging biohacking technologies can be responsibly integrated into health systems and personal wellness, guiding stakeholders toward innovation that is ethical, evidence-based, and inclusive.

Guiding questions

- What are the most promising biohacking innovations currently shaping the future of health optimization?
- How can neuroscience, AI, and personalized data be used to safely enhance human performance and well-being?
- What ethical considerations must be addressed as biohacking moves from the fringe to the mainstream?
- How should health systems and regulators engage with the growing consumer demand for self-optimization technologies?



Hon Weng Chong
Founder & CEO
Cortical Labs, Australia

Day 3: Tuesday, 17 April 2025

9:30 - 10:00

Top Targets for AI-enabled Drug Discovery

Panel discussion

AI is reshaping the future of drug discovery—from predictive modeling and molecular targeting to clinical trial design and accelerated development timelines. With the open-source release of AlphaFold 3 and continued advancements in machine learning, pharmaceutical innovators are increasingly leveraging AI to identify promising drug candidates, streamline R&D, and tackle complex diseases more efficiently. This panel will bring together leaders applying AI across biotech and pharma to explore emerging targets, evolving platforms, and the real-world impact of AI on drug development today.

Why now?

AI shows great potential to reduce the cost of introducing a new drug into the market (amounting to USD 1.3 billion on average), one of the most exorbitant health costs. The integration of AI in drug discovery is set to revolutionize pharmaceutical research, with the market projected to surge from USD 1.76 billion in 2024 to USD 13.44 billion by 2035, growing at a compound annual growth rate of 20%.

Impact goals

Enable better and more use of AI for drug discovery by creating shared understanding about the opportunities and challenges.

Guiding questions

- How is AI—particularly tools like AlphaFold 3—reshaping the early stages of drug discovery, from target identification to lead optimization?
- What are the most promising therapeutic areas or disease targets where AI is accelerating breakthroughs?
- How can biotech innovators and pharmaceutical companies collaborate to scale AI-driven models while maintaining scientific rigor and regulatory readiness?
- What are the current limitations of AI in drug discovery, and how can the field address challenges related to data quality, model transparency, and validation?



Dr. Thomas Clozel
Co-Founder and CEO
Owkin, USA



Dr. Stefan Frings
Chief Medical Officer
Pharma Development
Roche



Julia Miao
Deputy CEO and
Chief Financial Officer
Sihuan Pharmaceuticals,
China



Dr. Alex Zhavoronkov
Founder and CEO
Insilico Medicine, USA



Lina Shadid
Health Industries Lead
PwC Middle East

Moderator

10:00 – 10:30

AI-enabled Personalized Health Interventions

Panel discussion

AI is increasingly poised to revolutionize personalized healthcare by integrating an individual's genetic, metabolic, lifestyle, and environmental data. This approach promises to optimize prevention and care, offering tailored strategies that could significantly improve health outcomes and extend longevity. The application of AI in this context has the potential to shift healthcare from a one-size-fits-all model to a more precise, individualized approach, transforming how we prevent, diagnose, and manage health throughout life.

Why now?

Breakthroughs such as AI-powered multi-cancer detection tests, patient digital twins, AlphaFold 3, and wearable health technologies are accelerating the shift from reactive treatment to proactive, personalized prevention—enabling earlier interventions, improved outcomes, and a more efficient, data-driven healthcare system.

Impact goals

Identify most promising AI solutions for personalized health interventions to be scaled

Guiding questions

- What are the most promising applications of AI for personalized prevention under development?
- What are the main challenges to scaling the adoption of AI in this space?
- How can healthcare providers work with AI companies and governments to remove roadblocks to adoption?



Dr. Khalid Fakhro
Chief Research Officer
Sidra Medicine, Qatar



Hady A. Khoury
Chief Development Officer
Medable Inc., USA



Dr. Yoshihiko Nakamura
CEO, Kinescopic Inc., Japan
Professor, MBZUAI, UAE



Eddie Reilly
Head of Global Regulatory Affairs
and Chief Regulatory Officer,
Research and Development
Sanofi, France



Prof. Aymeric Lim Yu Tang,
CEO, National University
Hospital; Professor,
Department of Orthopedic
Surgery, National University
of Singapore, Singapore



Dr. Lars Hartenstein
Director of Healthy Longevity
McKinsey Health Institute,
France

Moderator

10:30 – 11:00

The Future of Implants and Brain Computer Interfaces (BCIs)

Panel discussion

Brain implants have demonstrated considerable potential in treating conditions like paralysis and Parkinson's disease, showing promising results in clinical trials. However, the introduction of foreign objects into the brain presents distinct risks, including complications related to infection, rejection, and long-term effects on brain function. As this technology advances, understanding both the therapeutic benefits and the potential dangers will be crucial in shaping its future role in treating neurological disorders.

Why now?

The global brain-computer interface market was projected to reach USD 2.44 billion in 2024, with an expected growth rate of 18.15% CAGR from 2025 to 2030.

Impact goals

Raise awareness among stakeholders about expected breakthroughs in brain-computer interfaces and related challenges to be addressed.

Guiding questions

- What is next for brain implants and brain-computer interfaces?
- How might they be further miniaturized and what new approaches or materials could offer breakthroughs for safer, long-lasting implants in the brain – and other organs?
- What are the risks and how can they be managed and regulated?



Dr. Miguel Angelo L. Nicolelis
Professor Emeritus of Neurobiology
Duke University, USA



Dr. Tom Oxley
Chief Executive Officer
Synchron, USA



Prof. Gregory A. Petsko
Professor of Neurology
Harvard Medical School
and Brigham & Women's
Hospital, USA



Kelsey Warner
Gulf Reporter
Semafor, UAE

Moderator

11:00 – 11:30

The Future of Data: Novel Sources

Panel discussion

The future of public health relies on harnessing data beyond traditional clinical and epidemiological sources. From environmental signals and mobility patterns to social media, wearables, global travel data, and large-scale electronic health records, a new generation of diverse and real-world data streams is transforming how we understand and respond to population-level health threats. When integrated with advanced analytics and AI, these novel sources can enhance early warning systems, improve disease forecasting, and inform more targeted, real-time interventions. This session explores how leaders across global health, technology, and policy are leveraging innovation to integrate non-traditional data and advanced analytics into public health decision-making. By bridging sectors and disciplines, they are shaping more resilient, responsive systems that are better prepared to tackle current and future global health challenges.

Why now?

In 2024–2025, over 100 countries expanded digital surveillance systems under the WHO Pandemic Accord, backed by funders like CEPI and the World Bank. AI tools, including large language models, now scan 100,000+ sources daily to detect outbreaks, misinformation, and behavioral risks.

Impact goals

To identify the most promising non-traditional data sources and analytic tools that can enhance early warning systems, improve disease forecasting, and strengthen real-time decision-making in public health at a global scale.

Guiding questions

- Which emerging data sources show the most promise for strengthening public health intelligence and early detection?
- How can AI and advanced analytics be used to translate complex, large-scale data into actionable health insights?
- What are the key challenges—technical, ethical, or institutional—to integrating non-traditional data into public health systems?
- How can collaboration across sectors unlock the full potential of novel data to build more responsive and equitable health systems?



Ali Hashemi
Co-Founder and CEO
meta[bolic], UAE



Dr. Kamran Khan
Founder and CEO
BlueDot, Canada



Dr. Sania Nishtar
CEO
GAVI, Switzerland



Prithviraj Pramanik
Co-founder and CEO
AQAI, India



Dr. Lars Hartenstein
Director of Healthy Longevity
McKinsey Health Institute
France

Moderator

11:30 – 12:00

Connected Health: The Future of Wearables and Home-Based Care

Panel discussion

Wearables and home health technologies are rapidly evolving from fitness trackers to sophisticated clinical tools that enable real-time monitoring, personalized insights, and proactive care. The next generation of connected health devices—powered by AI and advanced computing—promises to extend care beyond traditional settings, transforming how patients manage chronic conditions, recover from illness, and engage with their health. As these tools grow more accurate, interactive, and data-rich, they hold the potential to shift healthcare from reactive treatment to continuous, patient-centered support. This panel will explore the future of clinical-grade wearables, home diagnostics, and digital therapeutics—and how they're reshaping prevention, care delivery, and the healthcare experience.

Why now?

In 2024–2025, AI-enabled devices are capable of continuously monitoring vital signs, detecting early deterioration, and feeding real-time data into clinical workflows—ushering in a new era of decentralized, personalized care. With global wearable health tech expected to surpass \$200 billion by 2028, the time is now to scale these innovations and ensure they're meaningfully integrated into healthcare systems.

Impact goals

To identify strategic priorities and cross-sector collaboration opportunities that will accelerate the integration of connected health technologies—such as wearables and home diagnostics—into mainstream care, enabling more proactive, personalized, and scalable healthcare delivery models.

Guiding questions

- How are wearables and home-based health devices transforming clinical monitoring, chronic disease management, and recovery?
- What are the key considerations for integrating real-time patient data into clinical workflows in a way that supports—not overwhelms—care teams?
- How can industry leaders, biotech innovators, and care providers collaborate to validate, scale, and personalize home health technologies?
- What are the infrastructure, regulatory, and equity challenges in expanding access to connected health—and how can they be addressed?



Olfat Berro
Area Head Middle East
Roche Pharmaceuticals
Lebanon



Dr. Richard L. Lieber
Chief Scientific Officer
Shirley Ryan
AbilityLab, USA



Dr. James Mault
Chief Executive Officer
BioIntelliSense, USA



Ali Hashemi
Co-Founder and CEO
meta[bolic], UAE

Moderator

Join Abu Dhabi Global Health Week 2025

Join us at Abu Dhabi Global Health Week 2025 and be a part of shaping the future of global health. Whether you're an innovator, healthcare professional, or organisation, this is your chance to collaborate, network, and make a lasting impact.

Don't miss out - get involved today and contribute to the advancement of health and healthcare worldwide.

Four ways to participate



Sponsor

Elevate your brand's presence to 15,000 health professionals including ministers, policymakers, strategists, key stakeholders and influencers, through diverse branding and sponsorship opportunities.

Scan to enquire about sponsorship opportunities



Exhibit

Showcase your brand to a global audience. Booking an exhibitor stand provides direct access to a concentrated audience of potential customers, fostering lead generation and sales.

Scan to book your stand today



Visit

Our complimentary visitor passes offer access to Abu Dhabi Global Health Week's live stage sessions and global exhibition hall.

Scan to find out more




Delegate

Our delegate passes offer access to high-level conference sessions where global healthcare visionaries and innovators discuss how we can tackle the world's greatest healthcare challenges.

Scan to register your interest in attending as a delegate



Venue floorplan



FOUNDATION PARTNER

M2

ATRIUM | STAND NO: A050

ADNEC CENTRE ABU DHABI, UAE

Be part of the Abu Dhabi Global Health Week community



2025 partners, sponsors and supporters

HOSTED BY

دائرة الصحة
DEPARTMENT OF HEALTH



FOUNDATION PARTNER

M2

GLOBAL HEALTH AND LONGEVITY CHAMPION

PURSHALTH

HEALTHCARE SUSTAINABILITY PARTNER

AstraZeneca

HEALTHCARE TRANSFORMATION PARTNER

BURJEEL HOLDINGS

AHEAD TOGETHER IN HEALTH PARTNER

GSK

DRIVING INNOVATION IN HEALTHCARE PARTNER

Johnson & Johnson

THE MEDICINES PARTNER

Lilly
A MEDICINE COMPANY

AI INNOVATION PARTNER

Microsoft

BEYOND HEALTH PARTNER

novo nordisk

AN INNOVATIVE GLOBAL HEALTHCARE PARTNER

sanofi

ACCESS TO HEALTHCARE PARTNER

VIATRIS

LONGEVITY PARTNER

MSD

EMPOWERING SUSTAINABLE FUTURE THROUGH HEALTH INNOVATION PARTNER

NOVARTIS

HEALTHCARE ECOSYSTEM PARTNER

Roche

EDUCATION PARTNER

كليفلاند كلينك أبوظبي
Cleveland Clinic Abu Dhabi
Brought to you by M2

HEALTHCARE SECTOR SPONSORS

abbvie

Bristol Myers Squibb

Deloitte

GILEAD

Kite

JUVENESCENT

جامعة نيويورك أبوظبي
NYU ABU DHABI

ORGANON

Pfizer

KNOWLEDGE PARTNERS

pwc

FROST & SULLIVAN

McKinsey & Company

OliverWyman

apco

healthcare world

The National

INSIGHTS PARTNERS

PHRMAG

OFFICIAL ENGLISH NEWS PARTNER

U.S.-U.A.E. Business Council
usaabusiness.org

SUPPORTED BY

مركز أبوظبي للصحة العامة
ABU DHABI PUBLIC HEALTH CENTRE

Business France

CANADA-UAE BUSINESS COUNCIL

European Healthcare Investor Association

NCHL

PHRMAG

PORTUGUESE BUSINESS COUNCIL

CULTURAL AND DESTINATION PARTNER

abu dhabi
Convention & Exhibition Bureau

VENUE PARTNER

adnec centre
abu dhabi
مركز أدنيك أبوظبي

ORGANISED BY

dmg events



Abu Dhabi Global Health Week

HOSTED BY

دائرة الصحة
DEPARTMENT OF HEALTH



15 - 17 APRIL 2025

ADNEC CENTRE ABU DHABI, UAE

GET INVOLVED

DELEGATE REGISTRATION

✉ delegate@adghw.com

SPEAKER & CONFERENCE

✉ sales@adghw.com

EXHIBITION & SPONSORSHIP

✉ sales@adghw.com



#ADGHW #AbuDhabiGlobalHealthWeek

adghw.com

HOSTED BY



SUPPORTED BY



CULTURAL AND
DESTINATION PARTNER



VENUE PARTNER



ORGANISED BY

